Cancer Currents Highlights – The Emergence of Cancer Liquid Biopsies by NCI
National Cancer Institute shared a post on LinkedIn: .
“Go to any big cancer research meeting these days and one topic of frequent discussion will almost certainly be liquid biopsies.
At the 2024 American Association for Cancer Research annual meeting last month, the program was chock full of studies and sessions where liquid biopsies dominated the discourse. There were studies of tests that analyze blood, urine, and saliva for free-floating bits of tumor DNA or RNA, exosomes, and extracellular vesicles. Some of these tests are designed to try to identify cancer at its earliest stages, some to predict whether a patient might respond to a given therapy, and still others to monitor people undergoing treatment to see if it’s working.
Common to all liquid biopsies is that they offer ways of using body fluids to obtain critical information about a person’s cancer without resorting to invasive procedures like surgery to get a sample of a tumor.
Cancer Currents has been closely following the boom in liquid biopsy research, including a story we just published about a promising liquid biopsy for the early detection of pancreatic cancer.
So, in case you have missed our stories on cancer liquid biopsies, here’s an opportunity to catch up on where this exciting and potentially transformative technology is heading.
As always, we welcome your feedback on Cancer Currents. And if you know somebody with an interest in staying up to date on the latest in cancer research, please feel free to forward them this newsletter.
Carmen Phillips,
Managing Editor, Cancer Currents.”